• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, raised £3.1 million

December 17, 2019 By admin Leave a Comment

Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance our new molecular targeted systemic radiotherapy agents, EMT‑100 and EMT‑101 ready for clinic development. Current investors and one new investor supported the round.

EMT‑100 and EMT‑101 have been developed as therapeutic agents from the company’s clinical stage imaging agent EMI‑137 and hence may present a fast track opportunity to enter the exciting and rapidly developing arena of systemic radiotherapy.

EMT‑100 and EMT‑101 are comprised of peptides targeting c-Met, conjugated to a radionuclide. c‑MET is significantly over-expressed by many tumours compared with healthy tissue and EMI-100/101 selectively target c-MET to deliver a lethal dose of radiation directly to tumour cells, with minimal impact on surrounding tissues. They offer the potential to target many solid tumours as well providing new treatment options for currently difficult to treat cancers.

Dr. Bernhard Sixt, CEO of Edinburgh Molecular Imaging, said:

“We are pleased that EMI’s current and new investors have endorsed our new strategic plan to use our clinical stage c-MET targeting technology as a base for the development of systemic radiotherapy. In clinical trials our optical imaging agent EMI-137 has been administered to almost 100 cancer patients so far and has proven to be highly specific, safe and effective. The dosing and imaging windows indicate that the technology should be ideally suited to developing a cross‑cancer SR agent.”

The new investor Georges Aboud, Caribou Property Limited, commented,

“Our goal is to back companies with world class technology that can make an impact on patients’ lives. With this strategic development, EMI has become an attractive player in the exciting field of systemic radiotherapy and has an experienced team to maximise its potential.”

Liz Roper, Partner in Epidarex Capital and Director of EM Imaging added:

“We are excited to continue to support EMI in this significant expansion for the use of its molecular targeted agents into therapeutic applications in the rapidly developing area of systemic radiotherapy which is attracting a great deal of investor interest.”

About Edinburgh Molecular Imaging
EM Imaging’s highly novel c-MET receptor targeting technology platform targets disease at the molecular level. It was formed in 2014 by Epidarex Capital.

As c-MET receptors are expressed in most cancer types our newly developed systemic radiotherapy agents (EMT-100 series) offer potentially new cross cancer treatment options for currently difficult to treat cancers. The development of the new agents benefits from the preclinical and clinical data of the company’s clinical stage imaging agent (EMI-137) which successfully completed a CRC phase 2b study in November 2019. EMI-137 has been administered to almost 100 cancer patients so far and has proven to be highly specific, safe and effective.

EMI-137 allows physicians and surgeons to see disease in the body in real time during interventional procedures providing guidance for more accurate surgery.

For more information, please visit www.emimaging.com

Filed Under: PR Tagged With: EMI, Edinburgh Molecular Imaging, theragnostic agents

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Evolution of Luxury Watches
$300bn of trapped value in people’s homes
Specialty Food Association Reveals Specialty Food Sales of $175 billion in State of the Specialty Food Industry Report
AIML-powered trading is the future
Open Source eCommerce as a Viable Alternative
When synthetic biology will disrupt an industry?
The future belongs to AIML-powered ecommerce

Market Research Media

The latest consumer survey findings about streaming services
A six-step forecasting methodology
Military Applications of Extended Reality
NFTstockphotography.com (NFT Stock Photography): NFT Photography is The Next Big Thing
America’s 100 largest housing markets are overpriced
InfluenceMgmt.com (Influence Management): Formal vs Informal Influence
Blockchaining.ai: What is Blockchain Technology and Why is it Popular

Secondary Sidebar

Technologies

Samsung Electronics and Red Hat Announce Collaboration in the Field of Next-Generation Memory Software
Samsung Unveils ISOCELL Image Sensor with Industry’s Smallest 0.56μm Pixel
New Zealand’s leading port, Ports of Auckland, welcome the world’s first full sized, electric tugboat
World-first Integrated Testing Facility for Fusion Power Plant Equipment to be Constructed in Japan
Intel is rolling out new processors designed for data centers

Tech Events

Jamstack Conf 2022, November 7-8 2022, San Francisco and online
KubeCon + CloudNativeCon EU, May 4-7, 2021
Snowflake Concludes Its Largest-Ever Global User Conference with New Innovations to Drive Application Development and Increased Collaboration in the Data Cloud
Pre-Registration Opens for 2020 Flash Memory Summit, November 10-12, 2020
FPGA Conference Europe, July 5 – 7, 2022, NH München Ost Conference Center

Footer

Recent Posts

  • Plant-based food innovation company, TMRW Foods, raises C$2 million and prepares for North American launch with Sprouts Farmers Market
  • How to achieving gender balance in management teams
  • When you feel like you’re spiraling
  • After Successful Tax Season, Embedded Tax Platform April Raises $30M Series A from Fintech Veterans
  • Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future
  • Nautical Commerce Raises $30M to Scale Multi-Vendor Marketplace Technology
  • Token Announces $13 Million Series B Funding Round and Appointment of New CEO to Disrupt the Authentication Market
  • Konnecto Raises $21M to establish a new category in marketing technology
  • Sharebite, the Leading Food Benefits Platform, Announces Closing of $39 Million Series B Round
  • Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Dossier

Cambridge Quantum Computing Appoints Oxford University Professor Bob Coecke as Chief Scientist
There is a progress in discussions on a potential price cap on Russian oil
An approach to M&A that created more long-term value
PayPal To Acquire Paidy
Deloitte acquires cloud security orchestration provider CloudQuest

Press Media Release

Mkt Dev 2022
The first IOTSWC Digital Summit will tackle the deployment of Artificial Intelligence and Digital Twins
Russia is now just hours away from its first foreign default
insightsoftware’s Embedded Analytics Solutions Named A Leader in 2022 Business Intelligence Market Study by Dresner Advisory Services
The Salvation Army and Convoy of Hope Partner Together to Meet the Needs of Ukrainian Refugees

App Coding

Writing code on the fly
Distraction-free coding
monday.com Adds Built-In Monetization Solution to the apps marketplace
ScaleOut Software Announces Production Release of Redis®* Integration
Ondat 2.8 Arrives in GA with Increased Support for Stateful Workloads in Kubernetes

API Coding

What is an API Gateway?
Web3 can take power and control from BigTech
Apiip Expand IP To Location API Services to Verify 1 million+ Requests A Month
Fintech AI Leader Photon Commerce Partners With Identifee to Enable Banks to Instantly Digitize and Analyze Statements
LeadDev London! The event for engineering leaders

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT